Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · women with polycystic ovary syndrome
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number and type of adverse events · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Significant adverse events (seizures, thromboembolism) within 24 hours of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps
Tranexamic acid showed no clear difference in significant adverse events (seizures, thromboembolism) within 24… compared with placebo (saline solution or sterile water) (moderate certainty).
1 finding from 1 review
Primary outcome: adverse events (assessed at 3 months as minimum, moderate or severe) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review